4D Pharma PLC (LBPS) Stock Price, Forecast & Analysis
USA - NASDAQ:LBPS - US35085K1097 - ADR
LBPS Key Statistics, Chart & Performance
The current stock price of LBPS is 1.65 null. In the past month the price decreased by -50%. In the past year, price decreased by -84.79%.
LBPS Latest News, Press Relases and Analysis
LBPS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 41.24 | 858.31B | ||
| JNJ | JOHNSON & JOHNSON | 18 | 450.02B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.48 | 254.34B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.97 | 242.00B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.57 | 214.40B | ||
| MRK | MERCK & CO. INC. | 9.52 | 209.46B | ||
| PFE | PFIZER INC | 7.59 | 138.16B | ||
| SNY | SANOFI-ADR | 11.24 | 119.68B | ||
| GSK | GSK PLC-SPON ADR | 7.75 | 94.17B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.95 | 92.80B | ||
| ZTS | ZOETIS INC | 19.63 | 55.16B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 193.71 | 42.83B |
Related stock screener links
About LBPS
Company Profile
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
Company Info
4D Pharma PLC
9 Bond Court
LEEDS LS1 2JZ GB
CEO: Duncan Peyton
Employees: 95
Phone: 441138950130.0
4D Pharma PLC / LBPS FAQ
What does 4D Pharma PLC do?
4D Pharma Plc is a pharmaceutical company, which engages in the development of live bio therapeutics. The firm is focused on developing Live Biotherapeutic Products (LBPs), a class of drugs derived from the human gut microbiome. The firm's LBPs are biologics based on live organisms, namely single strains of bacteria. The company has developed MicroRx, its LBP discovery platform. MicroRx interrogates its library of bacterial isolates for therapeutic functionality and characterizes the bacterial isolates using a range of complementary tools and technologies. Its microbiome profiling platform, MicroDx, analyses the microbiome to aid the diagnosis and treatment of patients with its Live Biotherapeutics. Its MicroRx platform has generated a pipeline of development programs in therapeutic areas, including immuno-oncology, gastrointestinal (GI), respiratory, autoimmune and central nervous system (CNS) diseases. Its MicroRx enables the discovery of MRx-4DP0004, which is engaged in an ongoing Phase I/II with partly controlled asthma.
What is the stock price of 4D Pharma PLC today?
The current stock price of LBPS is 1.65 null. The price increased by 2.48% in the last trading session.
What is the dividend status of 4D Pharma PLC?
LBPS does not pay a dividend.
How is the ChartMill rating for 4D Pharma PLC?
LBPS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists LBPS stock?
LBPS stock is listed on the Nasdaq exchange.
Who owns 4D Pharma PLC?
You can find the ownership structure of 4D Pharma PLC (LBPS) on the Ownership tab.
LBPS Technical Analysis
LBPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to LBPS. Both the profitability and financial health of LBPS have multiple concerns.
LBPS Financial Highlights
Over the last trailing twelve months LBPS reported a non-GAAP Earnings per Share(EPS) of -3.24. The EPS decreased by -43.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -10376.92% | ||
| ROA | -125.66% | ||
| ROE | N/A | ||
| Debt/Equity | 0.42 |
LBPS Forecast & Estimates
6 analysts have analysed LBPS and the average price target is 7.52 null. This implies a price increase of 356.04% is expected in the next year compared to the current price of 1.65.